Receptor tyrosine kinases (RTKs) are a family of 58 proteins embedded in the surface of your cells that detect incoming chemical signals and relay instructions inward. They sit in the cell membrane with one end reaching outside the cell and the other extending into the cell’s interior, acting as molecular switches that control whether a cell grows, divides, moves, or dies. When these switches malfunction, the consequences range from metabolic disorders to cancer, which is why RTKs have become some of the most important drug targets in modern medicine.
How RTKs Are Built
Every receptor tyrosine kinase has three basic parts. The extracellular domain sticks out from the cell surface and serves as the antenna, shaped to grab onto a specific signaling molecule (called a ligand) like a growth factor or hormone. A short transmembrane segment anchors the receptor through the fatty membrane of the cell. And the intracellular domain, sitting inside the cell, contains the enzymatic machinery that actually fires off the signal.
That intracellular portion is what gives these receptors their name. It functions as a kinase, an enzyme that attaches small phosphate groups onto specific amino acids called tyrosines. This phosphate-tagging activity is the core mechanism by which RTKs pass messages along to downstream proteins inside the cell. Without it, the signal from outside would have no way to reach the cell’s internal machinery.
While all 58 human RTKs share this three-part architecture, the details vary considerably across the 20 recognized subfamilies. Fibroblast growth factor receptors, for instance, have antibody-like structural loops in their extracellular region. Discoidin domain receptors are unusual because they respond to collagen fibers in the tissue around cells rather than to dissolved growth factors. The insulin receptor stands apart structurally too: it’s permanently locked together as a pair of two-part chains held by chemical bonds, while most other RTKs exist as separate, individual molecules until they’re activated.
How RTKs Switch On
For decades, the textbook explanation was simple: a signaling molecule lands on the extracellular domain, two separate receptor molecules are pulled together into a pair (a dimer), and this pairing activates the enzyme inside the cell. That story turns out to be incomplete. Researchers have found that many RTKs already exist as inactive pairs on the cell surface before any signal arrives. Rather than forcing two lone receptors together, the ligand instead changes the shape of the pre-formed pair, unlocking its activity.
Once unlocked, the two receptors in the pair phosphorylate each other, a process called trans-autophosphorylation. Each receptor tags specific tyrosine residues on its partner. Some of these tagged sites lock the enzyme into its fully active shape. Others serve a different purpose entirely: they become landing pads for other proteins waiting inside the cell to pick up the signal and carry it forward. Certain RTKs, like the receptors for angiopoietins involved in blood vessel formation and the Eph receptors that guide developing nerve cells, need to assemble into even larger clusters beyond simple pairs before they fully activate.
Passing the Signal Downstream
Once an RTK lights up with phosphorylated tyrosines, those tagged sites attract a crowd of intracellular proteins. These proteins latch on using specialized recognition modules, two of the most important being the SH2 domain and the PTB domain. Each module reads a short sequence of amino acids surrounding the phosphorylated tyrosine like a barcode. Because different RTKs display different barcodes, each receptor recruits its own specific set of signaling partners, which is how one growth factor can trigger cell division while another triggers cell movement.
Some of the proteins that dock onto activated RTKs are enzymes that immediately begin their own chain of chemical reactions. Others are adaptor proteins with no enzymatic activity of their own. Instead, they act as molecular scaffolds, gathering additional signaling proteins into organized complexes right at the membrane. One well-studied example is the scaffold protein IRS-1, which docks onto the activated insulin receptor and then recruits further partners that ultimately control how your cells take up glucose.
Four Major Signaling Routes
RTKs feed into four primary signaling highways inside cells, each leading to different outcomes:
- The MAPK pathway is a central driver of cell proliferation, movement, and specialization. Signals cascade through a chain of kinases, ultimately switching on genes in the nucleus that push a cell to divide or migrate.
- The PI3K/Akt pathway generates a lipid signal at the inner surface of the cell membrane that recruits the protein Akt. Once activated, Akt suppresses the cell’s self-destruct programs and promotes survival, making this pathway critical in both normal tissue maintenance and cancer.
- The STAT pathway takes a more direct route. STAT proteins, once phosphorylated, pair up and travel straight to the nucleus, where they increase the activity of genes involved in cell growth.
- The PLC-gamma pathway triggers the release of calcium from internal storage compartments in the cell. The resulting spike in calcium concentration activates a separate set of enzymes that control everything from muscle contraction to immune cell activation.
Most activated RTKs fire up more than one of these pathways simultaneously. The exact combination and intensity determines whether a cell divides, changes shape, migrates to a new location, or specializes into a particular cell type.
The Insulin Receptor: A Metabolic Outlier
Among all 58 human RTKs, the insulin receptor is the odd one out. While virtually every other RTK is primarily concerned with controlling cell growth or specialization, the insulin receptor’s main job is metabolic regulation: coordinating how your body uses and stores energy. It also signals differently. Most RTKs directly phosphorylate the downstream proteins that dock onto them, but the insulin receptor instead phosphorylates a large intermediary substrate protein, which then goes on to engage the next layer of signaling partners. This extra step may help the insulin receptor fine-tune its metabolic instructions with greater precision.
RTKs and Cancer
Because RTKs are master regulators of cell growth, mutations that make them overactive are a common feature of cancer. A receptor stuck in the “on” position tells a cell to keep dividing regardless of whether a growth signal is actually present. These malfunctions take several forms: the gene encoding the receptor can be amplified so the cell makes too many copies, a point mutation can make the kinase fire without any ligand, or two genes can fuse together to create a permanently active hybrid protein.
RTK gene fusions appear at particularly high rates in certain tumor types. In thyroid cancers, about 7.8% of cases carry fusions involving the RET receptor. Lung cancers show RTK fusions in roughly 7.1% of cases, spread across several receptors: ALK fusions account for 4.2%, RET fusions for 1.3%, and ROS1 fusions for 1.2%. Bladder and other urological cancers tend to favor FGFR fusions, which make up about 80% of all RTK fusion events in that group.
Targeted Therapies That Block RTKs
The discovery that specific RTK mutations drive specific cancers opened the door to a generation of precision drugs called tyrosine kinase inhibitors (TKIs). These small molecules slip into the active site of the kinase domain and block its ability to add phosphate groups, effectively silencing the runaway signal. The approach has transformed treatment for several cancers that were once extremely difficult to manage.
The number of approved TKIs has grown rapidly. Drugs now target a wide range of RTK families: erdafitinib blocks all four FGFR receptors and is used in bladder cancer, while lorlatinib targets ALK and ROS1 fusions in lung cancer. Larotrectinib is notable for being one of the first “tumor-agnostic” cancer drugs, approved for any solid tumor carrying an NTRK gene fusion regardless of where in the body it originated. Gilteritinib targets the FLT3 receptor in acute myeloid leukemia, and capmatinib blocks the MET receptor in certain lung cancers.
Beyond small molecules, therapeutic antibodies can also target RTKs by binding to the extracellular domain and preventing ligand attachment or receptor pairing. The choice between a small-molecule inhibitor and an antibody depends on the biology of the specific receptor and the nature of the mutation driving the cancer. In some cases, patients eventually develop resistance as their tumors acquire new mutations that allow the kinase to work around the drug, prompting the development of second- and third-generation inhibitors designed to overcome those escape routes.